Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction
Mitul B. Kadakia(Brigham and Women's Hospital), Benjamin M. Scirica(Brigham and Women's Hospital), Nihar R. Desai(Princess Margaret Cancer Centre), Karen P. Alexander(Clinical Research Institute), Anita Y. Chen(University of Rochester Medicine), Stephen D. Wiviott(Brigham and Women's Hospital), JoAnne M. Foody(Association of Chartered Certified Accountants), Christopher P. Cannon(Brigham and Women's Hospital)
Cited by 71
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k